Video: Mechanism of Action | Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]

Esperoct^® Mechanism of Action

View our mechanism of action (MOA) video to see how Esperoct^® uses PEGylation to extend half-life.

Please see full Prescribing Information and Important Safety Information.

Play

Pause

Skip

Volume

Chapters

Transcript

References

video_su

Fullscreen

Esperoct^® Mechanism of Action

Chapters

Transcript

References

View our mechanism of action (MOA) video to see how Esperoct^® uses PEGylation to extend half-life.

Please see full Prescribing Information and Important Safety Information.

Return to overview

Chapters

Return to overview

Transcripts

Return to overview

References

Register to get the latest updates about Esperoct^®

Also available from Novo Nordisk:

Visit website
Prescribing Information

Selected Important Safety Information

Contraindications

Do not use in patients who have known hypersensitivity to Esperoct^® or its components, including hamster proteins

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct^® and administer appropriate treatment

Indications and Usage

Esperoct^® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Esperoct^® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

Do not use in patients who have known hypersensitivity to Esperoct^® or its components, including hamster proteins

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct^® and administer appropriate treatment
Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct^® or if the expected plasma Factor VIII activity levels are not attained

Adverse Reactions

The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Esperoct®

[antihemophilic factor (recombinant), glycopegylated-exei]

Esperoct^® Mechanism of Action